» Articles » PMID: 36774476

A Transdermal Treatment with MC903 Ameliorates Diet-induced Obesity by Reducing Visceral Fat and Increasing Myofiber Thickness and Energy Consumption in Mice

Overview
Publisher Biomed Central
Date 2023 Feb 11
PMID 36774476
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: MC903 is a synthetic derivative of vitamin D3 that has been designed to diminish its impact on calcium metabolism and is clinically used as a transdermal reagent for psoriasis. Animal studies showed that an oral or intraperitoneal vitamin D3 treatment prevented the development of obesity. In contrast, the bioavailability of orally administered vitamin D3 is reported to be low in obese patients. In the current study, we aimed to investigate the impact of a transdermal treatment with MC903 in established obese mice. We further studied the underlying mechanisms of MC903-mediated metabolic improvement.

Materials And Methods: Male C57BL/6 J mice were fed standard chow or a 60% high-fat diet (HFD) for 7 weeks, and a transdermal treatment with MC903 on the ear auricle was initiated thereafter. The metabolic profiles of mice were analyzed during 4 weeks of treatment, and mice were dissected for histological and gene expression analyses. The direct impacts of MC903 and vitamin D3 were investigated using 3T3-L1 adipocytes and C2C12 myotubes in vitro.

Results: HFD-fed mice showed significant increases in body and epididymal white adipose tissue (eWAT) weights with enlarged adipocytes. They exhibited glucose intolerance, decreased oxygen consumption, and chronic inflammation in eWAT. The transdermal treatment with MC903 significantly ameliorated these metabolic abnormalities in HFD-fed mice without affecting food consumption. In accordance with enhanced energy metabolism, myofiber diameters and the expression of uncoupling protein 3 (UCP3) in the gastrocnemius and soleus muscle were significantly increased in MC903-treated HFD mice. In addition, vitamin D3 and MC903 both suppressed adipogenic differentiation and enhanced lipolysis in 3T3-L1 adipocytes, and increased UCP3 expression in cultured C2C12 myotubes. Furthermore, MC903 increased oxygen consumption and UCP3 knockdown significantly decreased them in C2C12 myotubes.

Conclusions: A transdermal treatment with MC903 increased myofiber diameter and energy metabolism and decreased visceral fat accumulation, thereby improving obesity and glucose intolerance in mice.

Citing Articles

Deletion of platelet-derived growth factor receptor β suppresses tumorigenesis in metabolic dysfunction-associated steatohepatitis (MASH) mice with diabetes.

Wada T, Takeda Y, Okekawa A, Komatsu G, Iwasa Y, Onogi Y Sci Rep. 2024; 14(1):23829.

PMID: 39394459 PMC: 11470010. DOI: 10.1038/s41598-024-75713-6.


Antiobesity Drug Discovery Research: Models for Shortening the Drug Discovery Pipeline.

Radheshyam , Gauniya P, Semalty M, Semalty A Curr Drug Targets. 2024; 25(6):388-403.

PMID: 38500275 DOI: 10.2174/0113894501289136240312060838.

References
1.
Wada T, Ishikawa A, Watanabe E, Nakamura Y, Aruga Y, Hasegawa H . Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance. J Endocrinol. 2017; 235(3):179-191. DOI: 10.1530/JOE-17-0351. View

2.
Sergeev I . Vitamin D-Cellular Ca link to obesity and diabetes. J Steroid Biochem Mol Biol. 2015; 164:326-330. DOI: 10.1016/j.jsbmb.2015.11.008. View

3.
Oh J, Riek A, Darwech I, Funai K, Shao J, Chin K . Deletion of macrophage Vitamin D receptor promotes insulin resistance and monocyte cholesterol transport to accelerate atherosclerosis in mice. Cell Rep. 2015; 10(11):1872-86. PMC: 4495012. DOI: 10.1016/j.celrep.2015.02.043. View

4.
Kanda N, Hoashi T, Saeki H . Nutrition and Psoriasis. Int J Mol Sci. 2020; 21(15). PMC: 7432353. DOI: 10.3390/ijms21155405. View

5.
Kongsbak M, Levring T, Geisler C, von Essen M . The vitamin d receptor and T cell function. Front Immunol. 2013; 4:148. PMC: 3684798. DOI: 10.3389/fimmu.2013.00148. View